Tpst2 knock-down alone significantly reduced tumor growth and notably enhanced the efficacy of anti-PD1 therapy (Fig. 4b), suggesting Tpst2 inhibition combined with anti-PD1 as a novel therapeutic strategy in oncology. Here, TPST2 is linked to neoplasm.